Literature DB >> 21699480

Radiotherapy for atypical meningiomas.

Richard Mair1, Kevin Morris, Ian Scott, Thomas A Carroll.   

Abstract

OBJECT: The role of postoperative radiotherapy in patients undergoing first-time resection of WHO Grade II meningioma remains unclear as reflected by varied practices in published clinical studies and national professional surveys. Much of the relevant literature is based on pre-2000 WHO grading criteria for atypical meningiomas. Authors in this study set out to explore the role of postoperative radiotherapy in patients undergoing first-time surgery for WHO Grade II meningiomas diagnosed using revised WHO 2000 criteria, against a background of otherwise limited published literature on this issue.
METHODS: The authors retrospectively collected data on 114 consecutive patients who underwent first-time resection of WHO Grade II atypical meningiomas diagnosed using 2000 WHO criteria, and who variably underwent postoperative radiotherapy according to individual surgeon practices. Outcomes, including radiological recurrence, were submitted to Kaplan-Meier and Cox regression analyses.
RESULTS: Postoperative radiotherapy demonstrated a significant benefit only when patients who had undergone gross-total tumor resection and those who had undergone subtotal resection along with postoperative radiosurgery to the tumor remnant were excluded from analysis.
CONCLUSIONS: The authors have performed the largest study in the literature to examine the use of radiotherapy for WHO Grade II, atypical, meningiomas following a first-time resection. They suggest that radiotherapy is not appropriate after first-time resection of those lesions in which a gross-total resection (Simpson Grade 1 or 2) has been achieved. They also advise that any tumor remnant radiologically demonstrated on postoperative imaging should be treated with radiosurgery and that postoperative radiotherapy after a first-time resection should be reserved for tumor remnants too large for radiosurgery and for which a second staged operation is not planned.

Entities:  

Mesh:

Year:  2011        PMID: 21699480     DOI: 10.3171/2011.5.JNS11112

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  42 in total

1.  Stereotactic radiotherapy as primary definitive or postoperative treatment of intracranial meningioma of WHO grade II and III leads to better disease control than stereotactic radiotherapy of recurrent meningioma.

Authors:  Dorota Lubgan; Sandra Rutzner; Ulrike Lambrecht; Karl Rössler; Michael Buchfelder; Ilker Eyüpoglu; Rainer Fietkau; Sabine Semrau
Journal:  J Neurooncol       Date:  2017-06-30       Impact factor: 4.130

2.  Complex interactions between the components of the PI3K/AKT/mTOR pathway, and with components of MAPK, JAK/STAT and Notch-1 pathways, indicate their involvement in meningioma development.

Authors:  Elias A El-Habr; Georgia Levidou; Eleni-Andriana Trigka; Joanna Sakalidou; Christina Piperi; Ilenia Chatziandreou; Anastasia Spyropoulou; Rigas Soldatos; Georgia Tomara; Kalliopi Petraki; Vassilis Samaras; Athanasios Zisakis; Vassilis Varsos; George Vrettakos; Efstathios Boviatsis; Efstratios Patsouris; Angelica A Saetta; Penelope Korkolopoulou
Journal:  Virchows Arch       Date:  2014-08-22       Impact factor: 4.064

3.  Early or late radiotherapy following gross or subtotal resection for atypical meningiomas: Clinical outcomes and local control.

Authors:  Ammoren Dohm; Emory R McTyre; Michael D Chan; Claire Fan; Scott Isom; J Daniel Bourland; Ryan T Mott; Christina K Cramer; Stephen B Tatter; Adrian W Laxton
Journal:  J Clin Neurosci       Date:  2017-09-13       Impact factor: 1.961

Review 4.  Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review.

Authors:  Leland Rogers; Igor Barani; Marc Chamberlain; Thomas J Kaley; Michael McDermott; Jeffrey Raizer; David Schiff; Damien C Weber; Patrick Y Wen; Michael A Vogelbaum
Journal:  J Neurosurg       Date:  2015-01       Impact factor: 5.115

5.  Atypical and malignant meningioma: outcome and prognostic factors in 68 irradiated patients.

Authors:  Beatrice Detti; Silvia Scoccianti; Vanessa Di Cataldo; Eleonora Monteleone; Samantha Cipressi; Lorenzo Bordi; Gianni Pellicanò; Davide Gadda; Calogero Saieva; Daniela Greto; Guido Pecchioli; Annamaria Buccoliero; Marco Ceroti; Franco Ammannati; Giampaolo Biti
Journal:  J Neurooncol       Date:  2013-09-18       Impact factor: 4.130

6.  Extent of resection and survival outcomes in World Health Organization grade II meningiomas.

Authors:  Pranay Soni; Mark A Davison; Jianning Shao; Arbaz Momin; Diana Lopez; Lilyana Angelov; Gene H Barnett; Joung H Lee; Alireza M Mohammadi; Varun R Kshettry; Pablo F Recinos
Journal:  J Neurooncol       Date:  2020-11-17       Impact factor: 4.130

7.  Efficacy of postoperative radiotherapy for high grade meningiomas.

Authors:  Yunseon Choi; Do Hoon Lim; Kyungil Jo; Do-Hyun Nam; Ho Jun Seol; Jung-Il Lee
Journal:  J Neurooncol       Date:  2014-06-26       Impact factor: 4.130

8.  Chordoid meningioma: a retrospective series of seven consecutive cases.

Authors:  Emiliano Passacantilli; Gennaro Lapadula; Federico Caporlingua; Jacopo Lenzi; Manila Antonelli; Francesca Santoro; Antonio Santoro
Journal:  Neurol Sci       Date:  2013-04-18       Impact factor: 3.307

9.  A rare case of atypical skull base meningioma with perineural spread.

Authors:  Henry Walton; Simon Morley; Javier Alegre-Abarrategui
Journal:  J Radiol Case Rep       Date:  2015-12-31

Review 10.  Medical management of meningiomas.

Authors:  Wendy J Sherman; Jeff J Raizer
Journal:  CNS Oncol       Date:  2013-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.